1. Richters, A, Aben, KKH, Kiemeney, LALM. The global burden of urinary bladder cancer: an update. World J Urol 2020; 38: 1895–1904.
Google Scholar | Crossref | Medline2. Babjuk, M. Trends in bladder cancer incidence and mortality: success or disappointment? Eur Urol 2017; 71: 109–110.
Google Scholar | Crossref | Medline3. Hilton, S, Jones, LP. Recent advances in imaging cancer of the kidney and urinary tract. Surg Oncol Clin N Am 2014; 23: 863–910.
Google Scholar | Crossref | Medline4. Lee, CH, Tan, CH, Faria, SDC, et al. Role of imaging in the local staging of urothelial carcinoma of the bladder. Am J Roentgenol 2017; 208: 1193–1205.
Google Scholar | Crossref | Medline5. Galgano, SJ, Porter, KK, Burgan, C, et al. The role of imaging in bladder cancer diagnosis and staging. Diagnostics 2020; 10: 703.
Google Scholar | Crossref6. Balleyguier, C, Ayadi, S, Van Nguyen, K, et al. BIRADS classification in mammography. Eur J Radiol 2007; 61: 192–194.
Google Scholar | Crossref | Medline | ISI7. Weinreb, JC, Barentsz, JO, Choyke, PL, et al. PI-RADS prostate imaging - reporting and data system: 2015, version 2. Eur Urol 2016; 69: 16–40.
Google Scholar | Crossref | Medline | ISI8. Panebianco, V, Narumi, Y, Altun, E, et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018; 74: 294–306.
Google Scholar | Crossref | Medline9. Cochrane Training . Chapter 9: summarizing study characteristics and preparing for synthesis [Internet], https://training.cochrane.org/handbook/current/chapter-09 (accessed 18 June 2021).
Google Scholar10. Moher, D, Shamseer, L, Clarke, M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4: 1.
Google Scholar | Crossref | Medline11. Ouzzani, M, Hammady, H, Fedorowicz, Z, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev 2016; 5: 210.
Google Scholar | Crossref | Medline12. Cochrane Training . Chapter 25: assessing risk of bias in a non-randomized study [Internet], https://training.cochrane.org/handbook/current/chapter-25 (accessed 18 June 2021).
Google Scholar13. Takeuchi, M, Sasaki, S, Ito, M, et al. Urinary bladder cancer: diffusion-weighted MR imaging—accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009; 251: 112–121.
Google Scholar | Crossref | Medline | ISI14. Xiao, G-Q, Rashid, H. Bladder neck urothelial carcinoma: a urinary bladder subsite carcinoma with distinct clinicopathology. Int J Surg Pathol 2015; 23: 517–523.
Google Scholar | SAGE Journals | ISI15. Ueno, Y, Takeuchi, M, Tamada, T, et al. Diagnostic accuracy and interobserver agreement for the vesical imaging-reporting and data system for muscle-invasive bladder cancer: a multireader validation study. Eur Urol 2019; 76: 54–56.
Google Scholar | Crossref | Medline16. Ueno, Y, Tamada, T, Takeuchi, M, et al. VI-RADS: multiinstitutional multireader diagnostic accuracy and interobserver agreement study. AJR Am J Roentgenol. Epub ahead of print 29 July 2020. DOI: 10.2214/AJR.20.23604.
Google Scholar | Crossref17. Wang, H, Luo, C, Zhang, F, et al. Multiparametric MRI for bladder cancer: validation of VI-RADS for the detection of detrusor muscle invasion. Radiology 2019; 291: 668–674.
Google Scholar | Crossref | Medline18. Wang, Z, Shang, Y, Luan, T, et al. Evaluation of the value of the VI-RADS scoring system in assessing muscle infiltration by bladder cancer. Cancer Imaging 2020; 20: 26.
Google Scholar | Crossref | Medline19. Kim, SH. Validation of vesical imaging reporting and data system for assessing muscle invasion in bladder tumor. Abdom Radiol (NY) 2020; 45: 491–498.
Google Scholar | Crossref | Medline20. Barchetti, G, Simone, G, Ceravolo, I, et al. Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center. Eur Radiol 2019; 29: 5498–5506.
Google Scholar | Crossref | Medline21. Liu, S, Xu, F, Xu, T, et al. Evaluation of Vesical Imaging-Reporting and Data System (VI-RADS) scoring system in predicting muscle invasion of bladder cancer. Transl Androl Urol 2020; 9: 445–451.
Google Scholar | Crossref | Medline22. Vaz, A, Zaparolli, M. Diagnostic accuracy of retrospective application of the vesical imaging-reporting and data system: preliminary results. Radiol Bras 2020; 53: 21–26.
Google Scholar | Crossref | Medline23. Sakamoto, K, Ito, M, Ikuta, S, et al. Detection of muscle-invasive bladder cancer on biparametric MRI using Vesical Imaging-Reporting and Data System and Apparent Diffusion Coefficient values (VI-RADS/ADC). Bladder Cancer 2020; 6: 161–169.
Google Scholar | Crossref24. Arita, Y, Shigeta, K, Akita, H, et al. Clinical utility of the vesical imaging-reporting and data system for muscle-invasive bladder cancer between radiologists and urologists based on multiparametric MRI including 3D FSE T2-weighted acquisitions. Eur Radiol. Epub ahead of print 23 August 2020. DOI: 10.1007/s00330-020-07153-5.
Google Scholar | Crossref25. Yoshida*, S, Tanaka, H, Kijima, T, et al. MP80-03 staging accuracy of  Vesical Imaging-Reporting and Data System (VI-RADS) for bladder cancer. J Urol 2019; 201(Suppl 4): e1161–e1161.
Google Scholar | Crossref26. Hong, SB, Lee, NK, Kim, S, et al. Vesical imaging-reporting and data system for multiparametric MRI to predict the presence of muscle invasion for bladder cancer. J Magn Reson Imaging 2020; 52: 1249–1256.
Google Scholar | Crossref | Medline27. Makboul, M, Farghaly, S, Abdelkawi, IF. Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with Vesical Imaging Reporting and Data System (VI-RADS) application. Br J Radiol 2019; 92: 20190401.
Google Scholar | Crossref | Medline28. Del Giudice, F, Barchetti, G, De Berardinis, E, et al. Prospective assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its clinical impact on the management of high-risk non-muscle-invasive bladder cancer patients candidate for repeated transurethral resection. Eur Urol. Epub ahead of print 5 November 2019. DOI: 10.1016/j.eururo.2019.09.029.
Google Scholar | Crossref29. Marchioni, M, Primiceri, G, Delli Pizzi, A, et al. Could bladder multiparametric MRI be introduced in routine clinical practice? Role of the new VI-RADS score: results from a prospective study. Clin Genitourin Cancer 2020; 18: 409–415.e1.
Google Scholar | Crossref | Medline30. Del Giudice, F, Leonardo, C, Simone, G, et al. Preoperative detection of VI-RADS (Vesical Imaging-Reporting and Data System) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time-to-cystectomy: time to reconsider the need for primary deep trans-urethral resection of bladder tumor in case of locally advanced disease? BJU Int 2020; 126: 610–619.
Google Scholar | Medline31. Metwally, MI, Zeed, NA, Hamed, EM, et al. The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study. Eur Radiol. Epub ahead of print 19 February 2021. DOI: 10.1007/s00330-021-07765-5.
Google Scholar | Crossref32. Woo, S, Panebianco, V, Narumi, Y, et al. Diagnostic performance of vesical imaging reporting and data system for the prediction of muscle-invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Oncol 2020; 3: 306–315.
Google Scholar | Crossref | Medline33. Luo, C, Huang, B, Wu, Y, et al. Use of Vesical Imaging-Reporting and Data System (VI-RADS) for detecting the muscle invasion of bladder cancer: a diagnostic meta-analysis. Eur Radiol 2020; 30: 4606–4614.
Google Scholar | Crossref | Medline34. Woo, S, Panebianco, V, Narumi, Y, et al. Corrigendum to ‘Diagnostic performance of vesical imaging reporting and data system for the prediction of muscle-invasive bladder cancer: a systematic review and meta-analysis’ [European Urology Oncology 3 (2020) 306-315]. Eur Urol Oncol 2020; 3: 811.
Google Scholar | Crossref | Medline35. Del Giudice, F, Pecoraro, M, Vargas, HA, et al. Systematic review and meta-analysis of Vesical Imaging-Reporting and Data System (VI-RADS) inter-observer reliability: an added value for muscle invasive bladder cancer detection. Cancers 2020; 12: 2994.
Google Scholar | Crossref | Medline36. Mariappan, P, Lavin, V, Phua, CQ, et al. Predicting grade and stage at cystoscopy in newly presenting bladder cancers-a prospective double-blind clinical study. Urology 2017; 109: 134–139.
Google Scholar | Crossref | Medline37. James, ND, Pirrie, S, Liu, W, et al. Replacing TURBT with mpMRI for staging MIBC: pilot data from the BladderPath study. J Clin Oncol 2020; 38: 446–446.
Google Scholar | Crossref38. Grossman, HB, Natale, RB, Tangen, CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. New Engl J Med 2003; 49: 859–866.
Google Scholar | Crossref39. Becker, REN, Meyer, AR, Brant, A, et al. Clinical restaging and tumor sequencing are inaccurate indicators of response to Neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. Epub ahead of print 17 August 2020. DOI: 10.1016/j.eururo.2020.07.016.
Google Scholar | Crossref40. Nishimura, K, Fujiyama, C, Nakashima, K, et al. The effects of neoadjuvant chemotherapy and chemo-radiation therapy on MRI staging in invasive bladder cancer: comparative study based on the pathological examination of whole layer bladder wall. Int Urol Nephrol 2009; 41: 869–875.
Google Scholar | Crossref | Medline41. Nguyen, HT, Mortazavi, A, Pohar, KS, et al. Quantitative assessment of heterogeneity in bladder tumor MRI diffusivity: can response be predicted prior to Neoadjuvant chemotherapy? Bladder Cancer 2017; 3: 237–244.
Google Scholar | Crossref | Medline42. Ahmed, SA, Taher, MGA, Ali, WA, et al. Diagnostic performance of contrast-enhanced dynamic and diffusion-weighted MR imaging in the assessment of tumor response to neoadjuvant therapy in muscle-invasive bladder cancer. Abdom Radiol (NY) 2021; 46: 2712–2721.
Google Scholar | Crossref | Medline43. Necchi, A, Anichini, A, Raggi, D, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol 2018; 36: 3353–3360.
Google Scholar | Crossref | Medline44. Necchi, A, Raggi, D, Gallina, A, et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol 2020; 77: 439–446.
Google Scholar | Crossref | Medline45. Necchi, A, Bandini, M, Calareso, G, et al. Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: preliminary findings from the PURE-01 study. Eur Urol 2020; 77: 636–643.
Google Scholar | Crossref | Medline46. Bandini, M, Calareso, G, Raggi, D, et al. The value of multiparametric magnetic resonance imaging sequences to assist in the decision making of muscle-invasive bladder cancer. Eur Urol Oncol. Epub ahead of print 27 June 2020. DOI: 10.1016/j.euo.2020.06.004.
Google Scholar | Crossref47. Giacalone, NJ, Shipley, WU, Clayman, RH, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol 2017; 71: 952–960.
Google Scholar | Crossref | Medline48. Daneshmand, S, Ahmadi, H, Huynh, LN, et al. Preoperative staging of invasive bladder cancer with dynamic gadolinium-enhanced magnetic resonance imaging: results from a prospective study. Urology 2012; 80: 1313–1318.
Google Scholar | Crossref | Medline49. Kool, R, Marcq, G, El-Achkar, A, et al. Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: is post-treatment tumor bed biopsy always necessary? Urol Oncol. Epub ahead of print 23 October 2020. DOI: 10.1016/j.urolonc.2020.10.001.
Google Scholar